LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

LLY

1,015.16

+3.18%↑

JNJ

229.65

+0.21%↑

ABBV

214.18

+2.75%↑

UNH

390.74

+0.12%↑

AZN

184.55

+0.28%↑

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

3.53 -3.02

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.44

Max

3.64

Chiffres clés
By Trading Economics
Revenu	-8.5M -35M
Employés	106
EBITDA	-11M -37M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+72.84% upside

Dividendes
By Dow Jones
Prochains Résultats	19 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	131M 295M
Ouverture précédente	6.55
Clôture précédente	3.53

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

1.23 / 1.45 Support & Résistance

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 mai 2026, 23:10 UTC

Actions en Tendance

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principaux Mouvements du Marché

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Résultats

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Acquisitions, Fusions, Rachats

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Acquisitions, Fusions, Rachats

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Résultats

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Résultats

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Résultats

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Résultats

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Acquisitions, Fusions, Rachats

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Acquisitions, Fusions, Rachats

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Acquisitions, Fusions, Rachats

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Acquisitions, Fusions, Rachats

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Acquisitions, Fusions, Rachats

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Acquisitions, Fusions, Rachats

Vinci Buys Canada's Modern Group of Companies

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

72.84% hausse

Prévisions sur 12 Mois

Moyen 7 USD 72.84%

Haut 10 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

1.23 / 1.45Support & Résistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.